Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial
Article in EClinicalMedicine (September 2023)
The most recent citing publications are shown below. View all 37 publications that cite this research output on Dimensions.
Article in EClinicalMedicine (September 2023)
Article in Vaccine (June 2023)
Article in npj Vaccines (March 2023)